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Health systems are essential for suicide risk detection. Most efforts target people with mental health (MH) diagnoses, but this only
represents half of the people who die by suicide. This study seeks to discover and validate health indicators of suicide death among
those with, and without, MH diagnoses. This case-control study used statistical modeling with health record data on diagnoses,
procedures, and encounters. The study included 3,195 individuals who died by suicide from 2000 to 2015 and 249,092 randomly
selected matched controls, who were age 18+ and afﬁliated with nine Mental Health Research Network afﬁliated health systems. Of
the 202 indicators studied, 170 (84%) were associated with suicide in the discovery cohort, with 148 (86%) of those in the validation
cohort. Malignant cancer diagnoses were risk factors for suicide in those without MH diagnoses, and multiple individual psychiatricrelated indicators were unique to the MH subgroup. Protective effects across MH-stratiﬁed models included diagnoses of benign
neoplasms, respiratory infections, and utilization of reproductive services. MH-stratiﬁed latent class models validated ﬁve subgroups
with distinct patterns of indicators in both those with and without MH. The highest risk groups were characterized via high
utilization with multiple healthcare concerns in both groups. The lowest risk groups were characterized as predominantly young,
female, and high utilizers of preventive services. Healthcare data include many indicators of suicide risk for those with and without
MH diagnoses, which may be used to support the identiﬁcation and understanding of risk as well as targeting of prevention in
health systems.
Translational Psychiatry (2022)12:280 ; https://doi.org/10.1038/s41398-022-02051-4

INTRODUCTION
Suicide is a major public health concern. In the United States
(US), > 47,000 individuals died by suicide in 2019 [1] – a 25%
increase since 2000 [2]. There is an urgent need to develop and
implement effective strategies to prevent suicide using timely and
accurate data to detect individuals at risk and to inform clinical
outreach [3]. According to the most recent US National Strategy
for Suicide Prevention, healthcare settings are important for
suicide prevention [4–6], where they often target interventions to
patients ‘known’ to be at-risk. The ﬁrst step in the US suicide
research strategy is to determine how to best detect individuals
at-risk to strategically target suicide prevention [4].
Several innovative statistical models leveraging electronic
health records (EHR) or claims data have been developed to
better detect suicide risk in health systems [3], but there remain
important gaps. First, most US-based studies have examined
suicide ideation or attempt outcomes, and there remains an
unmet need to understand risk of suicide death. Second, most of
the known risk factors associated with suicide are mental health

(MH) diagnoses (including MH, substance use disorders, and prior
suicide attempts) [7–11]. Nonetheless, recent data show that while
over 83% of individuals make a healthcare visit before suicide,
50% do not have a MH diagnosis [12]. Furthermore, approximately
15% of the total US population has a MH diagnosis, and half of all
suicides occur among these individuals [13, 14]. However, the
other half of all US suicides occur among the 85% of the
population without a MH diagnosis [2, 12]. Thus, suicide risk
detection and prevention directed primarily towards individuals
with a known MH diagnosis can only reach half of all individuals
before their death. More information is needed to identify and
understand suicide risk among those without known suicide risk
factors.
While two-thirds of healthcare visits before suicide occur in
outpatient primary care, medical specialty settings, or the
emergency department without a documented MH diagnosis
[12, 15, 16], there is limited information on non-MH risk factors
that may support risk detection [15, 17–20]. Clinical data may
provide a solution.
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This study ﬁlls major gaps by leveraging standard EHR and
claims data to detect indicators of suicide risk and protection in
the largest case-control study of suicide mortality among
individuals receiving care in US health systems to date.
Importantly, this study compares models for both those with
and without MH diagnoses to juxtapose associated clinical
exposures in these groups.
METHODS
This case-control study was conducted within the Mental Health Research
Network (MHRN). MHRN is a NIMH-funded consortium of health systems
serving 30 million individuals per year. The 9 systems participating in this
study are Essentia Health (Minnesota), Harvard Pilgrim Healthcare
(Massachusetts), HealthPartners (Minnesota), Henry Ford Health System
(Michigan), and the Colorado, Georgia, Hawaii, Northwest, and Washington
state regions of Kaiser Permanente. The institutional review boards at each
system approved data use for this study.
Cases were deﬁned as individuals who died by suicide from January 1,
2000, through September 30, 2015, and were members of the participating
health systems for at least 10 months of the year before death. The 10month period is selected as individuals are often disenrolled from their
health plan during the month of their death. Suicide deaths were identiﬁed
by ICD-10 codes documented within ofﬁcial State government mortality
records, which are the State-level data that comprise the National Death
Index [21]. For each case, the date of death was used as a reference date to
select matched controls, which were individuals afﬁliated with the same
institution who did not die from suicide during that year. A total of 100
control individuals were randomly selected to match each case. The casecontrol study included 339,360 individuals—3,360 cases and 336,000
controls. Data were extracted for the 365-day period prior to the reference
date for each matched set to focus on near-term indicators. Childhood
(<18 years old) cases composed a minority of the sample (n = 165, 4.9%)
and were excluded from the analysis. The sample after exclusions was
252,287 adults —3,195 cases and 249,092 controls. Before performing
analyses, case-control sets were randomly split into discovery (2/3) and
validation (1/3) samples. The sample was also annotated by those with and
without a MH diagnosis (deﬁned by those with a past year ICD 9 mental
health diagnosis 290–319 or suicide attempt diagnosis E950-E959).
MHRN utilizes a virtual data warehouse to facilitate data sharing across
sites [22]. Healthcare indicators for analysis included diagnoses summarized at the ICD-9 sub-chapter level, procedures at the Current Procedural
Terminology (CPT) category level, and encounters at the subtype level,
including hospitalizations, emergency department visits, and both outpatient visits to primary care and medical specialty settings. Visits to
medical specialty settings were subdivided by clinical specialty.
For analysis, each healthcare indicator was treated as binary (“ever” = 1
or “never” = 0). Those indicators with less than 10 observations were
excluded from subsequent analyses. All data collected at day 0 (the
reference day), as well as emergency encounters on day 1 were excluded
to avoid including data from the actual suicide. After exclusions, the
analysis included 107 diagnosis sub-chapters, 67 procedure categories, and
28 encounter types.

Statistical Analysis
Supplementary Fig. 1 displays the analytical goals of the study (identiﬁcation of 1. healthcare indicators associated with suicide and 2) sub-groups
of at-risk patients) in the context of the methods and the corresponding
sample sizes. To account for the matched design, conditional logistic
regression models were used to test associations between suicide and
indicators. All models were adjusted for age and sex. Differential effects by
MH status were evaluated through the inclusion of a multiplicative
interaction term between MH diagnosis and each indicator, with
signiﬁcance assessed using a likelihood ratio test. To account for multiple
testing, indicators with false discovery rate adjusted p-values (FDR) < 0.05
were considered signiﬁcant in the discovery sample, and those with
unadjusted p-values <0.05 in the validation sample were considered
validated.
Following single indicator analyses that demonstrated heterogeneity by
MH status, two approaches were taken to assess multi-indicator
associations with suicide. First, separate multi-indicator models were
constructed for those with and without a MH diagnosis using conditional
logistic models ﬁt with a lasso penalty. These analyses were conducted

using the R package clogitL1 [23], with the lasso shrinkage parameter (λ)
determined using 10-fold cross-validation. For each stratum, discovery and
validation models were ﬁt using all indicators. For those indicators retained
in both models, a standard conditional logistic regression model was ﬁt to
calculate 95% conﬁdence intervals (95% CI) and tests for statistical
signiﬁcance in the full sample. The second approach was patient-centric,
utilizing latent class analysis (LCA) to determine the existence of distinct
risk sub-groups. LCA was stratiﬁed by MH status using the indicators
retained in both the stratum-speciﬁc discovery and validation multiindicator penalized models. For each LCA model, the number of classes
was determined based on the Bayesian information criterion (BIC) and
class interpretability in the corresponding discovery samples, and
conﬁrmatory LCA was performed to assess consistency of case percentages and utilization proﬁles in the corresponding validation samples. LCA
was performed using MPlus v8.3. All other analyses were performed using
R v3.6.1. The program and statistical code, data codebook, and dataset are
available upon request and approval by the study team.

RESULTS
Study sample description
Summary statistics for demographic variables are shown in
Table 1. Overall, cases were older (mean age for cases was 51.4
years and 48.1 years for controls) and more likely to be male (cases
77.5% and controls 46.2%). Cases were less likely to have
commercial insurance (cases 62.8% and controls 72.5%), more
likely to live in areas with lower education levels (cases 39.1% and
controls 36.9%), and had lower neighborhood household incomes
(case median = $65,567 and control median = $67,694). Table 1
also shows that case/control summary statistics were consistent
between discovery and validation samples.
Single healthcare indicator associations with suicide death
and heterogeneity by MH status
The single indicator association results are included in Supplementary Table 1. Overall, of the 202 indicators tested in the
discovery sample, 170 were signiﬁcantly associated with suicide
death (FDR < 0.05), and of these, 146 (86%) were also signiﬁcant in
the validation sample, including 78 diagnoses (77 increased/1
decreased risk), 45 procedures (44/1), and 21 encounter types (21/
0). The top ten most signiﬁcant, validated associations for each
indicator type are summarized in Table 2.
All indicators were evaluated for differential suicide risk by MH
status (Supplementary Table 2). Of the 202 individual healthcare
indicators, 44 had signiﬁcant interactions (FDR < 0.05) with MH
status in the discovery set, with 7 (16%) also signiﬁcant in the
validation (p < 0.05), with MH-stratiﬁed results displayed in Table 3.
Of note, malignant neoplasms were associated with >twofold
higher risk among those without MH diagnoses. Given these
differences, subsequent multi-indicator analyses were stratiﬁed by
MH status.
Multi-indicator associations with suicide by MH status
The results from the discovery/validation penalized conditional
logistic regression models stratiﬁed by MH status are displayed in
Supplementary Table 3. The MH model retained 87 indicators (46
diagnoses, 30 procedures, and 11 encounters), and in the
validation model, 49 indicators (24 diagnoses, 19 procedures,
and 6 encounters) were retained. Increased/decreased risk of
suicide was signiﬁcantly associated with 7/8 diagnoses, 9/2
procedures, and 2/0 encounters. The non-MH discovery model
retained 98 indicators (56 diagnoses, 29 procedures, and 13
encounters), and in the corresponding validation model, 51
indicators (25 diagnoses, 8 procedures, and 18 encounters) were
retained. Increased/decreased risk was signiﬁcantly associated
with 7/4 diagnoses, 5/4 procedures, and 2/2 encounters.
The full MH and non-MH samples were used to estimate 95%
CIs and signiﬁcance for indicators retained in the respective
validation models, and the results for those indicators that
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0.143
8,628 (10.4)

67,709 (28,736)

123 (11.5)
17,623 (10.6)

67,687 (28,490)

237 (11.1)

65,151 (28,039)

66,394 (28,521)

28,063 (16.9)
561 (26.3)

14,270 (17.2)
269 (25.3)

120,390 (72.5)
1332 (62.5)

Abbreviations: n indicates number of individuals, %, column percent, SD standard deviation.
*P values correspond to chi-squared tests for categorical variables and t-tests for continuous variables.

<0.001
67,694 (28,572)

26,251 (10.5)

65,567 (28,203)

360 (11.3)
Other

Median Household
Income, mean (SD)

42,333 (17.0)
830 (26.0)
Public

180,508 (72.5)
2005 (62.8)
Commercial

150,102 (60.3)
1852 (58.0)
No

Insurance, n (%)

91,960 (36.9)
1250 (39.1)

<0.001

<0.001

<0.001

673 (63.2)

634 (59.5)
100,161 (60.3)
1218 (57.2)

60,118 (72.4)

49,941 (60.2)

<0.001

0.852
30,850 (37.2)
61,110 (36.8)
846 (39.7)
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Yes

133,995 (53.8)
719 (22.5)
Female

Lower Education, n (%)

0.030

<0.001

0.014

251 (23.6)

404 (37.9)

89,441 (53.9)
468 (22.0)

44,554 (53.7)

<0.001
38,462 (46.3)
814 (76.4)
76,635 (46.1)
1662 (78.0)
115,097 (46.2)
2,476 (77.5)

<0.001
Sex, n (%)

Male

<0.001
48.13 (17.25)
51.71 (18.08)
<0.001
48.13 (17.16)
51.31 (18.26)
<0.001
48.13 (17.19)

Case
(n = 1065)
Case
(n = 2130)
p value*
Control
(n = 249,092)
Case
(n = 3195)

All

51.44 (18.20)
Age, mean (SD)

Table 1.

Demographic characteristics of study subjects by suicide case/control status.

Discovery

Control
(n = 166,076)

p value*

Validation

Control
(n = 83,016)

p value*
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remained statistically signiﬁcant are displayed in Fig. 1. For
diagnoses, several individual MH conditions increased risk,
including Other Psychoses (OR = 4.00, 95% CI 3.50–4.58) and
Personality Disorders and Other Nonpsychotic Mental Disorders
(OR = 3.58, 95% CI 3.00–4.29). In comparison, cancer diagnoses
had a unique increased risk among non-MH individuals, including
Malignant Neoplasms of Other and Unspeciﬁed Sites (OR = 4.29,
95% CI 2.95–6.23) and Malignant Neoplasm of Respiratory and
Intrathoracic Organs (OR = 2.90, 95% CI 1.66–5.06). In contrast,
Benign Neoplasms had protective effects for both non-MH
(OR = 0.65, 95% CI 0.50–0.85) and MH (OR = 0.68, 95% CI
0.55–0.84) individuals. The services related to Reproduction and
Development were protective in both models, although the effect
was more extreme in the non-MH (OR = 0.37, 95% CI 0.24–0.58)
relative to the MH (OR = 0.60, 95% CI 0.45–0.81) model.
For procedures, increased risk among MH individuals was
distinguished by procedures related to the Respiratory System
(OR = 1.95, 95% CI 1.50–2.52) and Psychiatry (OR = 1.24, 95% CI
1.08–1.43). In comparison, Radiology procedures (OR = 1.54,
95% CI 1.14–2.08) were signiﬁcant for the non-MH model. The
MH sample had a unique protective effect of Nursing Facility
Services (OR = 0.54, 95% CI 0.36–0.81). Non-MH individuals had
unique protective effects of Immunization Administration for
Vaccines/Toxoids (OR = 0.82, 95% CI 0.68–0.98), Preventive Medicine Services (OR = 0.74, 95% CI 0.62–0.88), and Ophthalmology
(OR = 0.76, 95% CI 0.64–0.90).
For encounters, increased risk among MH individuals was
distinguished by Non-Face-to-Face Non-physician Services (OR =
1.53, 95% CI 1.13–2.07), Acute Inpatient (OR = 1.47, 95% CI
1.21–1.79), and Ambulatory - Rehab (OR = 1.53, 95% CI 1.16–2.02).
For non-MH individuals, Other Non-overnight - Home Health
(OR = 1.53, 95% CI 1.16–2.00) and Radiology Only - Outpatient
Clinic (OR = 1.54, 95% CI 1.14–2.08) were associated with
increased risk. MH individuals had no encounter types with
protective effects, and non-MH individuals had protective effects
for Emergency - Hospital Ambulatory (OR = 0.53, 95% CI
0.40–0.70) and Email - Other Non-hospital (OR = 0.68, 95% CI
0.52–0.88).
Latent class analysis discovery and validation of distinct
patient suicide risk sub-groups
The top indicators that differentiate the LCA identiﬁed sub-groups
for both MH and non-MH samples are displayed in Fig. 2. For both
the MH and non-MH samples, the number of latent subgroups
was identiﬁed as ﬁve, based on lowest value past the inﬂection
point in the BIC curve (Supplementary Fig. 2) that also identiﬁed a
low-risk group. For the MH sample, the groups are labelled in
order of decreasing case percentage: Group 1 (10.0% of the
sample, 13.8% cases), Group 2 (16.1% of the sample, 11.0% cases),
Group 3 (26.0% of the sample, 4.1% cases), Group 4 (24.1% of the
sample, 3.6% cases), and Group 5 (23.8% of the sample, 1.9%
cases). Based on these values, Groups 1 and 2 were identiﬁed as
high-risk groups for suicide. Speciﬁcally, Group 1 had higher
proportions of many diagnosis sub-chapters, procedure types, and
encounter types, signifying a high utilization group with multiple
healthcare concerns. Group 2 had a similar but less extreme
proﬁle, and these individuals were also younger (39 years) and
more likely to be female. Group 5 had the lowest case prevalence.
This group was one of the youngest on average (44 years old), had
the lowest proportion of males, and the highest proportion of
routine/preventive health visits. Conﬁrmatory LCA of the ﬁvegroup solution in the validation sample yielded groups with
similar case percentages and healthcare indicator proﬁles (Fig. 3).
For non-MH individuals, he resulting groups and their
corresponding case proportions were: Group 1 (14.1% of the
sample, 2.7% cases), Group 2 (21.8% of the sample, 1.7% cases),
Group 3 (25.6% of the sample, 1.5% cases), Group 4 (25.3% of the
sample, 1.3% cases), and Group 5 (13.3% of the sample, 0.3%
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Table 2.

Univariate odds ratios for death by suicide adjusted by age and sex.
Discovery
OR (95% CI)

p value*

FDR-adjusted
p-value*

47.84 (38.52–59.40)

<0.001

<0.001

Validation
OR (95% CI)

p value*

FDR-adjusted
p-value*

43.70 (32.18–59.35)

<0.001

<0.001

Diagnosis Sub-Chapter
Poisoning by Drugs, Medicinal and
Biological Substances
Other Psychoses

10.41 (9.45–11.46)

<0.001

<0.001

9.96 (8.69–11.42)

<0.001

<0.001

Neurotic Disorders, Personality
Disorders, And Other
Nonpsychotic Mental Disorders

5.91 (5.41–6.45)

<0.001

<0.001

6.21 (5.48–7.03)

<0.001

<0.001

Organic Psychotic Conditions

5.65 (4.75–6.73)

<0.001

<0.001

6.39 (5.08–8.04)

<0.001

<0.001

Pain

4.44 (3.71–5.31)

<0.001

<0.001

4.15 (3.20–5.38)

<0.001

<0.001

Other Diseases of Respiratory System

4.23 (3.67–4.87)

<0.001

<0.001

4.55 (3.75–5.52)

<0.001

<0.001

Other Disorders of The Central
Nervous System

4.13 (3.59–4.76)

<0.001

<0.001

4.04 (3.31–4.94)

<0.001

<0.001

Persons Encountering Health
Services in Other Circumstances

2.99 (2.70–3.31)

<0.001

<0.001

2.97 (2.56–3.43)

<0.001

<0.001

Persons Encountering Health
Services for Speciﬁc Procedures and
Aftercare

2.54 (2.28–2.82)

<0.001

<0.001

2.24 (1.92–2.60)

<0.001

<0.001

Symptoms

2.52 (2.30–2.76)

<0.001

<0.001

2.58 (2.27–2.93)

<0.001

<0.001

Encounter Type
Nonacute Institutional Stay - Rehab

8.82 (5.85–13.32)

<0.001

<0.001

7.40 (4.07–13.45)

<0.001

<0.001

Acute Inpatient - Acute Inpatient

6.51 (5.87–7.22)

<0.001

<0.001

5.93 (5.11–6.88)

<0.001

<0.001

Nonacute Institutional Stay - Skilled
Nursing

4.08 (2.98–5.58)

<0.001

<0.001

3.32 (2.11–5.23)

<0.001

<0.001
<0.001

Emergency - Hospital Ambulatory

4.00 (3.64–4.39)

<0.001

<0.001

4.00 (3.50–4.57)

<0.001

Ambulatory - Observation Bed

3.30 (2.59–4.20)

<0.001

<0.001

2.25 (1.51–3.36)

<0.001

<0.001

Other Nonovernight - Home Health

2.59 (2.21–3.02)

<0.001

<0.001

2.50 (2.00–3.13)

<0.001

<0.001

Telephone - Other Nonhospital

2.25 (1.97–2.56)

<0.001

<0.001

2.18 (1.80–2.63)

<0.001

<0.001

Ambulatory - Hospital Ambulatory

1.85 (1.66–2.06)

<0.001

<0.001

1.85 (1.59–2.16)

<0.001

<0.001

Ambulatory - Outpatient Clinic

1.81 (1.58–2.07)

<0.001

<0.001

1.63 (1.36–1.97)

<0.001

<0.001

Other Nonovernight - Other
Nonhospital

1.80 (1.57–2.06)

<0.001

<0.001

1.44 (1.17–1.76)

<0.001

<0.001

Procedure Type
Critical Care Services

20.35 (17.41–23.79)

<0.001

<0.001

19.69 (15.73–24.65)

<0.001

<0.001

Drug Testing

13.17 (11.35–15.29)

<0.001

<0.001

15.12 (12.21–18.71)

<0.001

<0.001

Psychiatry

7.92 (7.17–8.74)

<0.001

<0.001

8.04 (6.99–9.25)

<0.001

<0.001

Hospital Inpatient Services

7.71 (6.85–8.67)

<0.001

<0.001

7.61 (6.44–8.99)

<0.001

<0.001

Therapeutic Drug Assays

6.59 (5.69–7.64)

<0.001

<0.001

7.36 (6.01–9.02)

<0.001

<0.001

Respiratory System

5.59 (4.64–6.73)

<0.001

<0.001

6.42 (5.06–8.14)

<0.001

<0.001

Emergency Department Services

4.65 (4.24–5.11)

<0.001

<0.001

5.10 (4.48–5.80)

<0.001

<0.001

Hydration, Therapeutic, Prophylactic,
Diagnostic Injections
and Infusions, and Chemotherapy
and Other Highly Complex
Drug or Highly Complex Biologic
Agent Administration

3.45 (2.99–3.96)

<0.001

<0.001

3.20 (2.62–3.91)

<0.001

<0.001

Cardiovascular

3.06 (2.78–3.37)

<0.001

<0.001

2.92 (2.55–3.33)

<0.001

<0.001

Hematology and Coagulation

2.25 (2.06–2.47)

<0.001

<0.001

2.37 (2.09–2.70)

<0.001

<0.001

Abbreviations: OR indicates odds ratio, 95% CI 95% conﬁdence interval, n number of individuals.
*Likelihood ratio test p value from a conditional logistic regression adjusted for age and sex.

cases). The noticeably high-risk Group 1 was the second oldest (59
years old) and contained much higher percentages of most
healthcare indicators with multiple concerns, similar to Groups 1
and 2 from the MH sample. Further, while Groups 3 and 4 where at
intermediate risk and had similar but less extreme healthcare

proﬁles, there was an additional disengaged, high risk group
(Group 2) unique to the non-MH sample. The lowest-risk Group 5
was the youngest (39 years), contained a low proportion of males
(5.6%), and displayed higher proportions of routine/preventive
visits – similar to Group 5 from the MH model. Conﬁrmatory LCA
Translational Psychiatry (2022)12:280
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1.82 (1.25–2.65)

Nonacute Institutional Stay Skilled
Nursing

3.41 (3.02–3.84) <0.001

0.002

<0.001

<0.001

2.20 (1.81–2.66)

<0.001

5.38 (2.80–10.36) <0.001

2.70 (2.05–3.57)

1.65 (1.34–2.03)

<0.001

<0.001

<0.001

<0.001

0.002

0.001

<0.001

Interaction p
value*
0.179

p value*

0.791

0.724

0.060

3.88 (3.28–4.59) <0.001

1.10 (0.64–1.92)

1.30 (0.99–1.71)

3.06 (2.58–3.62) <0.001

0.87 (0.30–2.47)

2.23 (1.87–2.67) <0.001

1.48 (0.83–2.63)

OR (95% CI)

p value*

0.205

<0.001

0.001

2.24 (1.71–2.93)

<0.001

6.46 (2.64–15.81) <0.001

2.57 (1.68–3.94)

1.65 (1.23–2.21)

8.28 (3.78–18.14) <0.001

1.24 (0.89–1.72)

7.69 (4.35–13.58) <0.001

OR (95% CI)

Non-Mental Health

Abbreviations: OR indicates odds ratio, 95% CI 95% conﬁdence interval.
*
Likelihood ratio test p-value from a conditional logistic regression adjusted for age and sex.
†Likelihood ratio test p-value for the multiplicative interaction effect of MH status-by-health care metric assessed in a conditional logistic regression adjusted for age and sex.

Emergency Department
Services

Procedure Type

1.40 (1.15–1.71)

Other Nonovernight Home Health

0.001

3.06 (2.71–3.45) <0.001

Emergency - Hospital
Ambulatory

Encounter Type

7.17 (3.89–13.22) <0.001

0.001

2.50 (1.43–4.38)

Malignant Neoplasms of
Respiratory
and Intrathoracic Organs

0.043

<0.001

p value*

1.26 (1.01–1.58)

6.78 (4.61–9.97)

OR (95% CI)

2.24 (1.97–2.54) <0.001

2.08 (1.42–3.07) <0.001

p value*

Services in Other
Circumstances

Persons Encountering Health

Malignant Neoplasms of
Other and Unspeciﬁed Sites

OR (95% CI)

Mental Health

Mental Health

Non-Mental Health

Validation

Discovery

Mental health stratiﬁed odds ratios for validated interactions between utilization features and mental health status.

Diagnosis Sub-Chapter

Table 3.

0.001

<0.001

0.008

<0.001

<0.001

0.009

<0.001

Interaction
p value†
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Fig. 1 Forest plots of odds ratios from multi-indicator models of suicide death among those A) with and B) without a mental health
diagnosis. Results in both panels are taken from conditional logistic regression models ﬁt to the full sample of those individual with and
without mental health diagnoses. For each model, indicators were selected from those that were retained in both the discovery and validation
penalized regression models, and only those that were statistically signiﬁcant (p < 0.05) in the full sample were included in these ﬁgures.

of the ﬁve-group solution resulted in both similar case proportions
and healthcare indicator proﬁles.
DISCUSSION
Clinical data can be used to better differentiate the structure of
suicide risk as well as to identify subgroups and service settings
that require additional attention for suicide prevention in health

systems. Importantly, this study employed multiple methods to
identify and validate individual clinical indicators and patterns of
those indicators, to better distinguish risk in not only those with
MH diagnoses, but also among those with previously unknown
risk factors. The insights into these groups with respective high
and low population suicide incidence can inform clinical outreach
and assessment strategies, and as such, this study adds multiple
clinically and methodologically signiﬁcant ﬁndings to the
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Fig. 2 Latent class analysis sub-group identiﬁcation based on health care indicators associated with suicide death in individuals A) with
and B) without a mental health diagnosis. For each mental health stratum, latent class analysis (LCA) was performed based on health care
indicators identiﬁed in the respective penalized regression models in the discovery sample. LCA was performed in the discovery sample (D),
followed by conﬁrmatory LCA in the validation sample (V). The frequency of cases is displayed overall and for each LCA sub-group for both D
and V samples. Within each stratum, the LCA sub-group-speciﬁc frequency are displayed for those health care indicators where at least 9 of
the 10 ratios of the pairwise group frequencies were >1.5 (ie. sub-group distinguishing indicators).

literature. The ﬁndings from the multi-indicator models and LCA
may be most relevant and can help inform future work to
determine how these complex indicators of risk can inform clinical
outreach.
First, this study conﬁrms prior research indicating that those
who die by suicide often have multiple chronic or complex
conditions [17, 24]. In both the MH and non-MH analyses,
individuals with the highest healthcare utilization had the greatest
risk for suicide, indicating an opportunity for intervention. Prior
studies have focused analyses on single clinical risk factors for
suicide [19, 25–27], but this study suggests that future research

Translational Psychiatry (2022)12:280

should also consider comorbidities to better distinguish risk.
Suicide prevention in health systems should focus on those
individuals who are frequent utilizers of services, potentially
indicating higher severity of multiple conditions.
Second, older individuals with MH conditions who have low
utilization may be at elevated risk. In contrast, younger females
who are more engaged in routine healthcare are at lower risk. The
Interpersonal Theory of Suicide indicates that isolation and
burdensomeness may be important indicators of suicide [28].
These ﬁndings collectively indicate that engagement or connectedness with health systems, particularly for regular routine care,
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may be protective. This emphasizes the importance of clinical or
community outreach in suicide prevention, especially for older
individuals or males who have become disconnected from care.
Third, while suicide prevention has traditionally focused on
individuals with MH conditions, we found many non-MH medical
indicators associated with suicide. This supports the importance of
ensuring use of low-intensity suicide risk detection methods such
as the implementation of EHR-based statistical models or routine
clinical screening and assessment [3, 29, 30] in primary care and
other non-behavioral health settings. Brief interventions, such as
safety or crisis response planning [31, 32], can be immediately
offered to those at higher risk in addition to the connection with
appropriate levels of follow-up specialty care.
Fourth, there were several novel protective factors for suicide
identiﬁed in the study. Past studies have found few clinical
protective factors for suicide. Benign cancer diagnoses were
associated with reduced risk and may indicate a positive life event
that contrasts other life stressors. Receipt of preventive services
and vaccinations, also associated with lower risk, may suggest that
those more engaged in overall health promotion and prevention
have lower risk. These factors deserve more in-depth study in
future research.
Fifth, the modeling plan implemented in this study was
particularly innovative. Risk detection models require prespeciﬁcation of exposure variables. Thus, recent predictive modeling
studies have focused primarily on behavioral health factors as
primary exposures [33–37]. MH conditions were the primary
factors used in risk detection in prior studies. This was important
and valuable given that health systems, including the Veterans
Health Administration, have begun implementing these models to
stimulate clinical action [3, 38]. However, the current study
uniquely identiﬁed non-MH clinical risk proﬁles that can help
detect risk among those without MH diagnoses and differentiate
risk among those with MH risk factors. The new models developed
and validated in this study can also provide guidance to improve
future models, including non-MH indicators.
These ﬁndings must be viewed in the context of limitations.
First, the study was conducted in large health systems among
individuals with health insurance. While the results are generalizable to those with many insurance types (public and commercial), individuals without insurance were not included. Second, this
study used ICD-9 diagnosis codes. Future studies should replicate
ﬁndings using ICD-10 codes recently implemented in practice.
Third, this study used a case-control design, which is efﬁcient for
the estimation of indictor effects. Future studies may leverage
these ﬁndings to inform absolute risk estimates using prospective
cohorts. Fourth, race/ethnicity was not included, as it was not
ascertained by health systems prior to 2009. While the participating systems are diverse, this may be important to include in future
models. Fifth, while the validation hold-out sample did not overlap
with those in the discovery, it was not possible to perform the
conﬁrmatory LCA in a separate set of health care systems. Finally,
all healthcare utilization occurring on the date of, or day prior to,
death were excluded to account for potential utilization that may
have been part of the suicide death.
Clinical data include a range of health indicators, both risk and
protective, which can be used to better detect suicide risk among
those without known MH diagnoses and to better distinguish risk
among those with MH diagnoses. These data can also inform
targeted clinical outreach, assessment, and follow-up to those at
highest risk. This may be particularly important for those with
multiple conditions and those disengaged from healthcare. Suicide
prevention efforts should span across the entire health system.
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